The record
| Class | ghrp |
|---|---|
| Also known as | Growth Hormone Releasing Peptide 6, Hexapeptide-2, HWAWFK-NH2, SKF 110679 |
| Chain length | - |
| Molecular weight | 873.0 Da |
| Half-life | <30 minutes |
| Route | SC/IM |
| Studied for | Not approved for therapeutic use |
| Research use | GH deficiency research, metabolic studies, muscle wasting research |
| What has been shown | Induces GH release in isolated rat pituitary; Increases circulating GH in rats (subcutaneous dosing); Increases food intake (central administration) |
| How it works | Ghrelin receptor (GHS-R) agonist that stimulates growth hormone release. Also acts as negative allosteric modulator of ghrelin signaling. |
| Patent status | expired |
| Regulatory status | research only |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Muscle Hypertrophy / Anabolic Signaling (affection, 56%)
- GH Pulsatility Environment (affection, 85%)
- Adult GH deficiency (illness, 60%)
- Anti-aging protocols (illness, 40%)
- Anti-aging therapy (illness, 60%)
- Body composition optimization (illness, 48%)
- Cognitive support (illness, 30%)
- Duchenne muscular dystrophy (illness, 30%)
- Growth hormone deficiency (illness, 40%)
- HIV-associated lipodystrophy (illness, 30%)
- Metabolic syndrome (illness, 40%)
- Neuromuscular diseases (illness, 30%)
- Pediatric growth hormone deficiency (illness, 60%)
- Visceral adiposity reduction (illness, 30%)
- Muscle loss or weakness (symptom, 67%)